Advancing safe and efficacious psilocybin-based treatments for mental health and neurodegeneration

Mycomedica Life Sciences is leveraging a novel dosing paradigm of psilocybin to enhance therapeutic outcomes and maximize patient access across a diverse range of CNS disorders. Founded by renowned mycologist Paul Stamets, the company leverages his multi-decade track record in award-winning mycology research, formulation, and development to revolutionize innovative low-dose psilocybin-based treatments.